Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients type 2 diabetes treated with canagliflozin plus teneligliptin

Miya, Aika; Nakamura, Akinobu; Cho, Kyu Yong; Kawata, Shinichiro; Nomoto, Hiroshi; Nagai, So; Sugawara, Hajime; Taneda, Shinji; Tsuchida, Kazuhisa; Omori, Kazuno; Yokoyama, Hiroki; Takeuchi, Jun; Aoki, Shin; Kurihara, Yoshio; Atsumi, Tatsuya; Miyoshi, Hideaki

Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients type 2 diabetes treated with canagliflozin plus teneligliptin

Miya, Aika; Nakamura, Akinobu; Cho, Kyu Yong et al.

Journal of Diabetes Investigation, 2021, 12(8), 1395-1399

Permalink : https://hdl.handle.net/2115/82877

このアイテムのアクセス数:476件（2026-08-17 20:46 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
JDI 12 1395-1399	pdf	400 KB	317

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/82877
タイトル	Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients type 2 diabetes treated with canagliflozin plus teneligliptin
著者	Miya, Aika ; Nakamura, Akinobu ; Cho, Kyu Yong ; Kawata, Shinichiro ; Nomoto, Hiroshi ; Nagai, So ; Sugawara, Hajime ; Taneda, Shinji ; Tsuchida, Kazuhisa ; Omori, Kazuno ; Yokoyama, Hiroki ; Takeuchi, Jun ; Aoki, Shin ; Kurihara, Yoshio ; Atsumi, Tatsuya ; Miyoshi, Hideaki
著者名 Miya, Aika
e-Rad_Researcher 70552420 著者名 Nakamura, Akinobu
著者名 Cho, Kyu Yong
著者名 Kawata, Shinichiro
e-Rad_Researcher 50862330 著者名 Nomoto, Hiroshi
e-Rad_Researcher 70507590 著者名 Nagai, So
著者名 Sugawara, Hajime
著者名 Taneda, Shinji
著者名 Tsuchida, Kazuhisa
著者名 Omori, Kazuno
著者名 Yokoyama, Hiroki
著者名 Takeuchi, Jun
著者名 Aoki, Shin
著者名 Kurihara, Yoshio
e-Rad_Researcher 20301905 著者名 Atsumi, Tatsuya
e-Rad_Researcher 30360902 著者名 Miyoshi, Hideaki
言語	英語
キーワード	glucose variability
	C-peptide
	sodium–glucose co-transporter 2 inhibitor
発行日	2021-08-10
出版者	John Wiley & Sons
収録物名	Journal of Diabetes Investigation
巻(号)	12(8)
ページ	1395-1399
抄録	Aims/Introduction To identify the effect of combination therapy with a dipeptidyl peptidase‐4 (DPP‐4) inhibitor and a sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor compared with switching from a DPP‐4 inhibitor to a SGLT2 inhibitor on improving the glucose variability in patients with or without impaired endogenous insulin secretion. Materials and Methods A secondary analysis regarding the relationship between endogenous insulin secretion and the change in mean amplitude of glycemic excursions (ΔMAGE) was conducted in a multicenter, prospective, randomized, parallel‐group comparison trial that enrolled patients with type 2 diabetes who had been taking teneligliptin and were treated by switching to canagliflozin (SWITCH) or adding canagliflozin (COMB). Participants were categorized into the following four subgroups: SWITCH or COMB and high or low fasting C‐peptide (CPR) divided at baseline by the median. Results ΔMAGE in the COMB group was greatly improved independent of a high or low CPR (-29.2±28.3 vs. -20.0±24.6, respectively; P=0.60). However, ΔMAGE was not ameliorated in the low CPR SWITCH group, and the ΔMAGE was significantly smaller than that in the high CPR COMB group (P<0.01). Conclusions COMB would be a better protocol rather than switching teneligliptin to canagliflozin to improve daily glucose variability in patients with impaired endogenous insulin secretion.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
権利情報	Creative Commons Attribution 4.0 International
PISSN	2040-1116
EISSN	2040-1124
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1111/jdi.13479